Product Overview
Composition
One capsule contains:
400 mg of glycerylphosphorylcholine hydrate (choline alfoscerate) as an active substance;
Excipients:
glycerol (glycyrin)
purified water.
Capsule shell:
medical gelatin,
glycerol (glycerin),
methyl parahydroxybenzoate (methyl paraben),
propyl parahydroxybenzoate (propyl paraben),
iron oxide red oxide
titanium dioxide
purified water,
sorbitol (sorbitol).
pharmachologic effect
Pharmacotherapeutic group: nootropic agent
ATX code: [N07AX02]
Pharmacological action
Central cholinostimulator, which contains 40.5% metabolically protected choline (metabolic protection promotes the release of choline in the brain). When ingested, it is split by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neural membrane.
Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. It increases the linear blood flow velocity on the side of the traumatic brain injury, helps to normalize the spatio-temporal characteristics of the spontaneous bioelectrical activity of the brain; has a positive effect on cognitive and behavioral reactions of patients with vascular diseases of the brain.
It improves brain functions by acting on the pathogenetic factors of involutional psycho-organic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dose-dependently stimulates the release of acetylcholine; participating in the synthesis of phosphagidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, and receptor function. It does not affect the reproductive cycle and does not have teratogenic and mutagenic effects.
Pharmacokinetics
Absorption - 88%), easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45%) from that in the plasma). It is excreted mainly by the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and through the intestines (15%).
ATX code: [N07AX02]
Pharmacological action
Central cholinostimulator, which contains 40.5% metabolically protected choline (metabolic protection promotes the release of choline in the brain). When ingested, it is split by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neural membrane.
Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. It increases the linear blood flow velocity on the side of the traumatic brain injury, helps to normalize the spatio-temporal characteristics of the spontaneous bioelectrical activity of the brain; has a positive effect on cognitive and behavioral reactions of patients with vascular diseases of the brain.
It improves brain functions by acting on the pathogenetic factors of involutional psycho-organic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dose-dependently stimulates the release of acetylcholine; participating in the synthesis of phosphagidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, and receptor function. It does not affect the reproductive cycle and does not have teratogenic and mutagenic effects.
Pharmacokinetics
Absorption - 88%), easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45%) from that in the plasma). It is excreted mainly by the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and through the intestines (15%).
Indications
- acute and recovery periods of severe traumatic brain injury and ischemic stroke, recovery period of hemorrhagic stroke, proceeding with focal hemispheric symptoms or symptoms of damage to the brain stem;
- psycho-organic syndrome against the background of degenerative and involutional changes in the brain;
- chronic cerebrovascular insufficiency;
- cognitive impairment (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate) including dementia and encephalopathy.
- senile pseudomelancholy.
Contraindications
Hypersensitivity, pregnancy, breastfeeding.
Side effects
Allergic reactions, nausea (due to dopaminergic activation).
Interaction
Not found.
How to take, course of administration and dosage
In acute conditions: intramuscularly or intravenously (slowly) at 1.0 g (1 ampoule) per day for 10-15 days, then they switch to taking capsules orally at 0.8 g (2 capsules) in the morning and 0.4 g (1 capsule) in the afternoon within 6 months
In chronic conditions: inside of 0.4 g (1 capsule) 3 times a day, preferably before meals.
The duration of treatment is 3-6 months.
Overdose
Symptoms : dyspeptic disorders.
Special instructions
If nausea occurs after taking the drug, the dose should be reduced.
Cerepro does not affect the speed of psychomotor reactions.
Release form
Capsules
Storage conditions
In a dry, dark place and out of the reach of children at a temperature of 25 ° C.
Shelf life
2 years.